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Abstract
The important role of APOAV gene T-1131>C variant in determination of plasma triglyceride levels
has been proved on many population studies. Recently, associations between C-1131 allele and
higher mother's height as well as with longer fetal birth length were suggested.
In 1,305 females, aged between 28 and 67 years and having at least one child, we have analyzed a
putative association between T-1131>C APOAV variant (analyzed by PCR and restriction analysis)
and body height.
Mother's body height did not differ between T/T homozygotes (N = 1093, 162.5 ± 6.5 cm) and C
allele carriers (N = 212, 162.1 ± 6.4 cm). Thus we have failed to confirm, that mothers with APOAV
C-1131 allele are higher than T/T-1131 homozygotes.
Introduction
We read with interest the study by Ward et al. [1] on the
association between the T-1131>C APOAV  variant and
plasma levels of triglycerides in pregnancy. In agreement
with some previously published population's studies with
different design [2-8], they described an association
between higher levels of plasma triglyceride and the pres-
ence of C-1131 allele also in a group of healthy pregnant
women. Additionally, they have found an interesting
association between allele C-1131 and higher mother's
height and as well as with fetal birth length.
The T-1131>C variant has been intensively studied over
the last couple of years. The C allele is undoubtedly asso-
ciated not just with higher plasma TG levels [2-7], but also
with higher VLDL-TG levels [9] what could influence fetal
growth [10,11] and theoretically also final height of the
body in adulthood, as suggested by Ward et al. [1].
Discussion
Using a previously described method [5,12], we analyzed
the T-1131>C variant in a total of 1,367 unrelated Cauca-
sians females aged 48.8 ± 10.6 years in 2000/2001
recruited as a representative 1% population sample [Mul-
tinational monitoring of trends and determinants in cardiovas-
cular diseases: MONICA Project, Manual of operations
WHO/MNC 82.2, Nov 1983]. Written informed consent
was obtained before the blood samples were taken and
measurements being performed. 62 females have no chil-
dren. In 1,305 females, having at least one child, we have
analyzed a putative association between APOAV  T-
1131>C variant and body height by ANOVA. The size of
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the analyzed population minimized the chances of false
negative or false positive results.
As mentioned before, standard association between ele-
vated levels of plasma triglycerides and the presence of the
C-1131 allele was found [5,6].
In contrast to Ward et al. [1], we found no association
between the T-1131>C variant in the APOAV gene and
mother's body height, see Table 1. Thus the association
described by Ward et al. [1] need not be generally valid.
Plasma triglycerides represent the most important source
of fatty acids utilized by fetus through pregnancy. About
50% of these fatty acids are derived from maternal circu-
lation [13]. It has been found that maternal VLDL-TG con-
centrations are positively correlated with birth weight
[10,11]. In respect of these findings the same effect of
VLDL-TG concentrations on birth length could be sup-
posed. However results reveal that birth length seemed to
be affected by many maternal factors [10] shading
expected effect of TG.
Nevertheless, adult body height, which slightly correlate
with birth length, although undoubtedly genetically
determined, will be in last century strongly influenced by
abundant availability of food sources in industrially
developed countries and this environmental effect could
mask the influence of the genes.
Conclusions
More than 1300 unrelated Caucasian females were
included in this study. We conclude that the T-1131>C
variant in the APOAV  gene has no general effect on
mother's body height. Nevertheless, APOAV gene and its
variants [3,14] remain to be candidate gene for genetic
determination of newborn's length/weight.
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Table 1: APOAV T-1131>C variant and height in women
APOAV genotype T-1131T + C-1131
N1 0 9 3 2 1 2
Height (cm) 162.5 ± 6.5 162.1 ± 6.4
Data are presented as means ± s. d. No significant association was 
found.